Underlying conditions and trigger diseases for the development of aHLH: comparison of (A) the global perspective, summarized by Ramos-Casals et al,6 and (B) the highly selected refractory aHLH cohort studied by Wang et al.1 Of note, given the restricted composition of trigger diseases, the prospectively designed salvage trial for aHLH with DEP regimen achieved meaningful results, whereas a one-size-fits-all treatment algorithm is not appropriate for all potential aHLH patients, as causes and trigger diseases are highly heterogeneous, requiring individualized, risk-adapted treatment.5 Hem NPL, hematologic neoplasia; HSCT, hematopoietic stem cell transplantation; NPL, neoplasia; Organ-sp AID, organ-specific autoimmune disease; SLE, systemic lupus erythematosus.

Underlying conditions and trigger diseases for the development of aHLH: comparison of (A) the global perspective, summarized by Ramos-Casals et al, and (B) the highly selected refractory aHLH cohort studied by Wang et al. Of note, given the restricted composition of trigger diseases, the prospectively designed salvage trial for aHLH with DEP regimen achieved meaningful results, whereas a one-size-fits-all treatment algorithm is not appropriate for all potential aHLH patients, as causes and trigger diseases are highly heterogeneous, requiring individualized, risk-adapted treatment. Hem NPL, hematologic neoplasia; HSCT, hematopoietic stem cell transplantation; NPL, neoplasia; Organ-sp AID, organ-specific autoimmune disease; SLE, systemic lupus erythematosus.

Close Modal

or Create an Account

Close Modal
Close Modal